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Abstract
Background: MicroRNAs are a family of 19- to 25-nucleotides noncoding small RNAs that primarily function as gene
regulators. Aberrant microRNA expression has been described for several human malignancies, and this new class of small
regulatory RNAs has both oncogenic and tumor suppressor functions. Despite this knowledge, there is little information
regarding microRNAs in plasma especially because microRNAs in plasma, if exist, were thought to be digested by RNase.
Recent studies, however, have revealed that microRNAs exist and escape digestion in plasma.
Methodology/Principal Findings: We performed microRNA microaray to obtain insight into microRNA deregulation in the
plasma of a leukemia patient. We have revealed that microRNA-638 (miR-638) is stably present in human plasmas, and
microRNA-92a (miR-92a) dramatically decreased in the plasmas of acute leukemia patients. Especially, the ratio of miR-92a/
miR-638 in plasma was very useful for distinguishing leukemia patients from healthy body.
Conclusions/Significance: The ratio of miR-92a/miR-638 in plasma has strong potential for clinical application as a novel
biomarker for detection of leukemia.
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Introduction
microRNAs are small endogenous non-coding RNAs that
posttranscriptionally repress the expression of protein-coding
genes by base-pairing with the 39 untranslated regions (UTRs) of
the target messenger RNAs (mRNAs) [1]. These single-strand
RNAs are considered to play crucial roles in many normal cellular
processes, such as proliferation, development, differentiation and
apoptosis by inhibiting target gene(s) expression through imperfect
pairing with target mRNAs, inducing direct mRNA degradation
or translational inhibition [2,3,4,5]. In addition, recent studies
have shown that the deregulation of microRNA expression
contributes the multistep processes of carcinogenesis in human
cancer either by oncogenetic or tumor suppressor function [6,7].
Therefore, microRNA expression patterns (or signatures) are now
known to characterize the developmental origins of tumors more
effectively than mRNA expression signatures and may provide a
useful tool for the diagnosis and prognosis of human cancer.
The search for non-invasive tools for the diagnosis and
management of cancer has long been a goal of cancer research,
and it could greatly reduce the worldwide health burden of cancer
[8]. Although conventional strategies for blood-based biomarker
discovery (e.g., using proteomic technologies) have shown promise,
novel approaches that can complement and improve on current
strategies for cancer detection are urgently needed. Recently, it has
been reported that microRNAs are circulating in serum [9,10] and
tumor-derived microRNAs such as miR-155, miR-21, miR-15b,
miR-16 and miR-24 are detectedinthe plasmasand serumsoftumor
patients [11,12]. These might be a new class of effective biomarkers,
and we expect that the microRNAs abundance profile in plasma
might reflect physiological and/or pathological conditions.
In this study, we focused whether circulating microRNAs can be
detected in plasma and whether expression levels of specific
microRNAs differ between leukemia patients [several type of acute
myeloid leukemia (AML) and acute lymphoblastic leukemia
(ALL)] and healthy individuals. Our results have revealed that
the decrease of miR-92a in the plasma is a novel class of blood-
based leukemia biomarkers, and furthermore raised provocative
questions regarding the mechanism of stability and potential
biological function of circulating microRNAs.
Results
Expression profiling of microRNAs in normal human plasma
Mitchell et al. have reported that ninety-one mature micro-
RNAs are present in human plasma, and the endogenous plasma
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activity [12]. Therefore, we also analyzed the expression profile of
microRNAs in human plasma using microarrays. We found that
148 microRNAs presented in seven normal plasma samples
(Figure 1A). Unfortunately, it was difficult to compare these signal
intensities because there was great variability of the values among
the samples. However, the rank order of signal intensity of each
microRNA among all of the detected microRNAs in a sample was
similar to that in the other samples (Figure 1B). Especially, the
signal of miR-638 was the top rank regardless of the sexes and
ages. These data suggested that miR-638 was physiologically
necessary in blood, and might be a useful internal control for
quantification of microRNAs in plasma. Our results of the
microRNA expression profiles were somewhat different from
previously reported data [10,12]. The difference may be possible
to owe to the different technical platform.
Microarray analysis of the microRNAs in the plasma of
leukemia patients
Above results led us to determine whether tumor-related
microRNAs enter the circulation at levels sufficient to be
measurable as biomarkers for leukemia detection. To identify
the differentially expressed microRNAs in the plasmas of acute
leukemia patients, we first screened leukemia samples using
microarrays. Experiments were performed with total RNA isolated
from the plasmas of two acute myeloid leukemia (AML) leukemia
samples. We found that the rank order of signal intensities of miR-
92a was dramatically down in the leukemia samples (Figure 2A).
The ratio of miR-92a and miR-638 serves as leukemia
biomarkers
We next analyzed the levels of miR-92a in the plasma samples
from normal (n=16) and leukemia (AML, n=54; ALL, n=7) by
TaqMan qRT-PCR. In order to improve the precision of the data,
we tried to use the miR-638 as standardization. Interestingly, the
ratio of miR-92a to miR-638 in all of the plasma samples from the
leukemia patients were decreased compared with that from the
normal donors (Figure 2B).
High expression of miR-92a in tumor cells of acute
leukemia
Next, we examined the expression level of miR-92a in leukemic
cells. We performed in situ hybridization using locked nucleic acid
(LNA)-modified probes digoxigenin (DIG) labelled. We examined
4 cases of AML and 2 cases of ALL, and found that miR-92a was
strongly expressed in leukemic cells from both AML and ALL
(Figure 3, Case 1–3). In contrast, we did not detect miR-92a
expression in normal blasts.
Discussion
In this report, we describe that the ratio of miR-92a/miR-638
in plasma was the very sensitive marker for AML and ALL. There
was no relationship between the subtypes of AML and ALL (data
not shown). Recently, microRNA expression profiling studies
revealed that t(8;21), inv(16), t(15;17) and MLL/11q23 have
unique microRNA expression signatures capable of distinguishing
them from other subtypes of AML [13,14,15]. In addition, it has
been reported that up-regulation of miR-155 in AML patients
with an internal tandem duplication (ITD) of the FLT3 gene
[13,16,17]. These observations suggest that microRNA expression
is associated with cytogenetics and molecular alterations in AML.
On the other hand, we observed decrease of miR-92a in all plasma
samples of AML and ALL. One case in the samples showing the
miR-92a decrease has t(4;11)(q21;q23) translocation. These data
indicate that microRNA expression signature in plasma will serve
as a valuable diagnostic and prognostic marker that adds
information beyond the cytogenetics. The decrease of miR-92a
in the plasma may be a very useful clinical marker of acute
leukemia.
Figure 1. Expression profiling of microRNAs in normal plasmas.
A. MicroRNA expression profiles in seven normal samples by microRNA
microarray analysis. Y axis represents relative intensity of hybridization
signals. B. Comparison of the signal intensities of various microRNAs
among normal plasmas. The signal intensity of each microRNA by
microarray analysis is evaluated as a rank order among the detected
microRNAs. Y axis represents log10 (Rank of signal intensity in each
sample/average rank of that in all samples).
doi:10.1371/journal.pone.0005532.g001
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blood vessels and why miR-92a is decreased in plasma of the acute
leukemia patients are intriguing questions but remain unclear.
Interestingly, miR-92a is transcribed from miR-17-92 locus that
encode the polycistronic precursor containing seven microRNAs:
miR-17-5p, miR-17-3p, miR-18, miR-19a, miR-20, miR-19b and
miR-92a, and the human microRNA cluster miR-17-92 is
amplified and/or overexpressed in several cancers such as acute
myeloid leukemia [15,18], malignant lymphoma [19], lung cancer
[20], thyroid cancer [21] and hepatocellular carcinoma [22].
Furthermore, inhibition of miR-17-5p and miR-20a with antisense
oligonucleotides (ONs) can induce apoptosis selectively in lung
cancer cells overexpressing miR-17-92 [23]. All together, these
results suggest that miR-92 has oncogenic potential. Interestingly,
we revealed that discrepant expression of miR-92a between
leukemic cells and the plasmas of leukemic patients. At the time we
speculate that miR-92a is an essential molecule for proliferation of
cells, and cancer cells both actively transcribe miR-92a and take in
miR-92a from the blood. Exosomes are small (50–90 nm)
membrane vesicles of endocytic origin that are released into the
extracellular environment on fusion of multivesicular bodies
(MVB) with the plasma membrane [24]. Many cells including
reticulocytes [25], dendritic cells [26], B cells [27], T cells [28],
mast cells [29], epithelial cells [30] and tumor cells [31] have the
capacity to release exosomes, and exosomes contain both mRNAs
and microRNAs, which can be delivered to another cell and
function in a new location [32]. In addition, endogenous plasma
microRNAs exist in a form that is resistant to RNase activity in
plasma [12]. These studies suggest that microRNAs are packaged
inside exosomes that are secreted from cells. Thus, it might be
possible that cancer cells specifically take in the exosome that
contain miR-92a and, as a result, miR-92a decreases from the
blood. As an alternative explanation, cancer cells may specifically
digest miR-92a in the plasma directly or indirectly. Nevertheless, it
is still unclear that selective decrease of miR-92a in acute
leukemia, and we need to study the mechanism of microRNA
circulation. Future studies may reveal how these microRNAs
influence primate physiology. In addition, many microRNAs
expressed in tumor tissues may influence the biological behavior
and clinical phenotype of the tumor. Although the functional roles
of microRNAs in tumor biology are unrevealed, we envision that
blood-based microRNA biomarkers will predict clinical behavior
and/or therapeutic response.
In summary, we have shown that the ratio of miR-92a/miR-
638 in blood is firmly associated with diagnosis in acute leukemia
patients. This data suggest that the amount of microRNAs in
plasma have potential as non-invasive biomarkers of cancer,
including hematopoietic neoplasia.
Materials and Methods
Plasma collection and RNA isolation
Whole blood samples were collected from healthy donors and
the patients with AML and ALL at Tokyo Medical University
Hospital (Tokyo, Japan). This study was approved in June 2008 by
institutional review board (IRB) of Tokyo Medical University
(No. 930), and all subjects provided written informed consent
under institutional review board. Details of clinical data are
provided in Table 1. Whole blood was separated into plasma and
cellular fractions by centrifugation at 16006g for 15 min. Total
RNA in the plasma was isolated using Isogen-LS (NIPPON
GENE) according to the manufacture’s instructions. For RNA
isolation from plasma, 250 ml of plasma was homogenized in
750 ml of Isogen-LS. Then 200 ml of chloroform was added to the
sample and the mixed solution was centrifugated. After an
additional chloroform extraction and precipitation with isopropa-
nol, the RNA sample was suspended in 20 ml of nuclease free
water. In general, we obtained 400 ng of RNA from 1 ml of
plasma.
Figure 2. Comparison of microRNA expressions in the plasmas
of normal and acute leukemia. A. Comparison of signal intensity
ranks of various microRNAs in normal (n=7) and leukemia (n=2)
plasmas by microarray analysis. Y axis represents mean ratio of the
signal intensity rank of leukemia to the rank of normal of each
microRNA. B. Comparison of the ratio of miR92a signal intensity to miR-
638 signal intensity by TaqMan qRT-PCR among the plasmas of normal
and leukemia. Mann-Whitney’s U test was used to determine statistical
significance.
doi:10.1371/journal.pone.0005532.g002
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To monitor the changes in microRNA levels associated with AML,
100 ng of total RNA was labeled and hybridized using Human
microRNA Microarray Kit (Agilent Technologies) according to
manufacture’s protocol (Protocol for use with Agilent microRNA
microarrays Version 1.5). Hybridization signals were detected with
DNA microarray scanner (Agilent Technologies) and the scanned
images were analyzed using Agilent feature extraction software. The
data discussed in this manuscript have been deposited in NCBI’s
Gene Expression Omnibus and are accessible through GEO Series
accession number GSE14772: http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token=tdabvuqcakymoxi&acc=GSE14772.
Quantitative RT-PCR of mature microRNAs
MicroRNAs were quantified using TaqManH MicroRNA
Assays (Applied Biosystems) with modifications. Briefly, 20 ng of
total RNA was reverse transcribed (RT) by TaqManH MicroRNA
RT Kit. 15 ml of RT reactions contained 106RT buffer, 0.15 ml
of 100 mM dNTPs with dTTP, 0.188 ml of RNase-inhibitor
(20 units/ml), 1 ml of MultiScribe
TM Reverse Transcriptase
(50 units/ml), 1 ml of each of microRNA specific stem-loop
primers (has-miR-92, 4374013; has-miR-638, 4380986; Applied
Biosystems) and 10.16 ml of input RNA. The mixture was
incubated at 16uC for 30 min, 42uC for 30 min and 85uC for
5 min. Subsequently, quantitative real time-PCR was performed
using Mx3005P
TM QPCR System (STRATAGENE). For a 20 ml
of PCR reaction, 206 TaqManH MicroRNA Assays in which
PCR primers and probes (59-FAM and 39-TAMRA) were
contained, 1 ml of RT product diluted 1:2 with nuclease-free
water and 10 mlo f2 6 TaqManH Universal Master Mix, No
AmpEraseH UNG (Applied Biosystems) were mixed. The reaction
was first incubated at 95uC for 2 min, followed by 50 cycles of
95uC for 15 sec and 60uC for 1 min. Data were analyzed with
MxPro–Mx3005P version 3.00 (STRATAGENE), with the
automatic Ct setting for adapting baseline and threshold for Ct
determination. Mann-Whitney’s U test was used to determine
statistical significance between control and test group. P values less
than 0.05 were considered significant.
In situ hybridaization of miR-92a
Locked nucleic acid (LNA)-modified probes for miR-92a and
negative control (miRCURY-LNA detection probe, Exiqon). The
probe sequences were as follows; miR-92a,5 9-ACAGGCCGGGA-
CAAGTGCAATA-39; a scrambled oligonucleotides used for
negative control, 59-GTGTAACACGTCTATACGCCCA-39.
In situ hybridization was performed using the RiboMap in situ
hybridization kit (Ventana Medical Systems) on the Ventana
Discovery automated in situ hybridization instrument (Ventana
Medical Systems). The in situ hybridization steps after the
deparaffinization step were performed based on the standard
Figure 3. MicroRNA expression in leukemic cells. In situ hybridization was performed using LNA probes for miR-92a and negative control. Blue
signals represent positive for the microRNAs. Bars indicate 50 mm.
doi:10.1371/journal.pone.0005532.g003
Table 1. Summary of clinical detalis of acute leukemia
patients used for analysis.
n(%)
Sex
Men 39(51%)
Women 38(49%)
Total 77(100%)
Control 16(19%)
French-American-British classification
AML M0 2(3.2%)
AML M1 11(18.0%)
AML M2 19(31.1%)
AML M3 10(16.3%)
AML M4 3(4.9%)
AML M4Eo 1(1.6%)
AML M5 1(1.6%)
AML M5b 1(1.6%)
AML M6 1(1.6%)
AML M7 2(3.2%)
AML with multilineage dysplasia 3(4.9%)
ALL L2 2(3.2%)
ALL Ph + 1(1.6%)
ALL preB 4(6.5%)
Acute leukemia Total 61(100%)
doi:10.1371/journal.pone.0005532.t001
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note (http://www.ventanamed.com). The initial fixation step was
performed by incubating the sections in formalin-based RiboPrep
reagent (Ventana Medical Systems) for 30 min at 37uC. After acid
treatment using hydrochloride-based RiboClear reagent (Ventana
Medical Systems) for 10 min at 37uC, the slides were treated with
the ready-to-use protease 2 reagent. The sections were hybridized
with the anti-sense LNA (Locked Nucleic Acid) riboprobe (2 ng/
slide) using RiboHybe hybridization buffer (Ventana Medical
Systems) for 6 h at 37uC after an initial denaturing pre-
hybridization step for 6 min at 70uC. After a low-stringency wash
with 26RiboWash (Ventana Medical Systems) for 6 min at 42uC,
a second washing step was performed using 16RiboFix reagent
for 20 min at 37uC followed by incubation of biotin-labeled anti-
digoxigenin antibody (Sigma) for 30 min at 37uC. After incubating
the streptavidin-alkaline phosphatase conjugate for 16 min at
37uC, signal was detected using the BlueMap NBT/BCIP
substrate kit for 4 h at 37uC. Finally, the sections were
counterstained with Kernechtrot as a marker stain and covered
with a glass coverslip.
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